The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...

Eli Lilly’s stock has climbed almost 60% this year and trades for more than $900. The pharma giant also has seen soaring ...

We recently compiled a list of the 10 Best Counter Cyclical and Defensive Stocks to Invest In. In this article, we are going ...

Ashkenazi was CFO at Lilly from 2021 until leaving the company this summer. Like Montarce, she joined Lilly in 2001. During ...

Deutsche Bank analyst James Shin has maintained their bullish stance on LLY stock, giving a Buy rating on September 16. James Shin has given ...

Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...

The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...

On Friday, the U.S. Food and Drug Administration approved Eli Lilly's eczema drug for use in adults and children 12 and older ...

Many of the industry’s glitzy new buildings are showcasing impressive artwork by artists dealing with homelessness or living ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 597.82% and currently trading at $922.59.The company has been around since 1876 and ...

Eli Lilly and Company (NYSE: LLY) today announced the appointment of Lucas Montarce as executive vice president and chief financial officer (CFO) and member ...